Search results (840)
« Back to PublicationsValidation of an algorithm for selection of SGLT2 and DPP4 inhibitor therapies in people with type 2 diabetes across major UK ethnicity groups: a retrospective cohort study.
Journal article
Güdemann LM. et al, (2026), Lancet Reg Health Eur, 61
Estimating the risk of cardiovascular outcomes and all-cause mortality in individuals with type 2 diabetes: Validation of the UKPDS outcomes model using TECOS and EXSCEL data.
Journal article
Coleman RL. et al, (2026), Diabetes Obes Metab, 28, 1068 - 1075
The Role of Adaptive and Innovative Trial Designs in Diabetes Research: A Scoping Review.
Journal article
Goshrani A. et al, (2026), Diabetes Care, 49, 197 - 210
Blood pressure lowering in isolated diastolic hypertension and cardiovascular risk: an individual patient data meta-analysis.
Journal article
Bidel Z. et al, (2025), Eur Heart J
Clinical perspectives of new insights and tools to minimize the hypoglycaemia burden connected with type 2 diabetes pharmacotherapy.
Journal article
Standl E. et al, (2025), Cardiovasc Diabetol, 24
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects.
Journal article
Chadwick J. et al, (2025), J Clin Pharmacol, 65, 1460 - 1473
International Variation in Case Fatality After Major Coronary or Cerebrovascular Events in Individuals With Type 2 Diabetes: Evidence From ADVANCE, TECOS, and EXSCEL.
Journal article
Clarke PM. et al, (2025), Diabetes Care, 48, 1925 - 1931
Impact of changes in conventional risk factors induced by once-weekly GLP-1 receptor agonist exenatide on cardiovascular outcomes: an EXSCEL post hoc analysis.
Journal article
Coleman RL. et al, (2025), Cardiovasc Diabetol, 24
Proteomic pathways across the ejection fraction spectrum in patients with heart failure and diabetes mellitus: an EXSCEL trial substudy.
Journal article
Peters AE. et al, (2025), Sci Rep, 15
Evaluating prediction of short-term tolerability of five type 2 diabetes drug classes using routine clinical features: UK population-based study.
Journal article
Cardoso P. et al, (2025), Diabetes Obes Metab, 27, 4320 - 4329
Risk factors for bone fractures in type 2 diabetes and the impact of once-weekly exenatide: insights from an EXSCEL post-hoc analysis.
Journal article
Maddaloni E. et al, (2025), Diabetes Res Clin Pract, 223
Response to Comments on Maddaloni et al. Osteoprotegerin, Osteopontin, and Osteocalcin Are Associated With Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL. Diabetes Care 2025;48:235-242.
Journal article
Maddaloni E. et al, (2025), Diabetes Care, 48, e61 - e62
Effects of intensive blood pressure treatment on orthostatic hypertension: individual level meta-analysis.
Journal article
Juraschek SP. et al, (2025), BMJ, 388
Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities.
Journal article
Loesch DP. et al, (2025), Nat Commun, 16
ive-drug class model using routinely available clinical features to optimise prescribing in type 2 diabetes: a prediction model development and validation study.
Journal article
Dennis JM. et al, (2025), Lancet, 405, 701 - 714